LOGIN  |  REGISTER
C4 Therapeutics
Recursion

Varex Imaging Management to Present in Upcoming Investor Conferences

March 11, 2025 | Last Trade: US$11.97 0.08 0.67

SALT LAKE CITY / Mar 11, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at the following upcoming investor conferences.

  • Oppenheimer’s 35th Annual MedTech & Services Virtual Conference: Monday, March 17, 2025 at 12:00pm ET. Webcast link here.
  • Sidoti Small Cap Virtual Conference: Wednesday, March 19, 2025 at 12:15pm ET. Webcast link here.

The webcast can be accessed at the above links or on Varex’s website at http://www.vareximaging.com/news.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page